DCF — ASPIRE HEALTH PARTNERS INC
Enterprise Value: $-24.7M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-24.7M
Enterprise Value
$-10.6M
PV of Cash Flows
$-14.1M
PV of Terminal Value
$-22.7M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $105.6M | $0.2M | 0.0% | $-4.3M | $-3.9M |
| Year 2 | $108.8M | $1.3M | 1.0% | $-3.3M | $-2.7M |
| Year 3 | $112.0M | $2.5M | 2.0% | $-2.3M | $-1.7M |
| Year 4 | $115.4M | $3.1M | 3.0% | $-1.8M | $-1.2M |
| Year 5 | $118.9M | $3.5M | 3.0% | $-1.7M | $-1.0M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-24.7M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$102.5M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.002991306639132183
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5